Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -19.30% is 27% below its 5-year average of -15.18%, near the low end of its 5-year range (-22.82%–-6.72%).
1.48% above its 12-month average of -19.59%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -4.81%.
RETURN ON ASSETS (ROA)
-19.30%
RETURN ON ASSETS (ROA) AVG TTM
-19.59%
RETURN ON ASSETS (ROA) AVG 3Y
-15.38%
RETURN ON ASSETS (ROA) AVG 5Y
-15.18%
RETURN ON ASSETS (ROA) AVG 10Y
-22.33%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+1.48%
CURRENT VS 3Y AVG
-25.45%
CURRENT VS 5Y AVG
-27.14%
CURRENT VS 10Y AVG
+13.57%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.81%
median of 841 covered companies
CURRENT VS SECTOR MEDIAN
+39.33%
vs the sector median at left
MaxCyte, Inc.
Market Cap
$113.01M
Return on Assets (ROA)
-19.30%
TTM Avg
-19.59%
3Y Avg
-15.38%
5Y Avg
-15.18%
Market Cap
$111.94M
Return on Assets (ROA)
-85.80%
TTM Avg
-37.85%
3Y Avg
-56.27%
5Y Avg
-56.27%
Market Cap
$112.69M
Return on Assets (ROA)
-167.64%
TTM Avg
-183.95%
3Y Avg
-119.46%
5Y Avg
-95.34%
Market Cap
$112.51M
Return on Assets (ROA)
-48.90%
TTM Avg
-85.01%
3Y Avg
-256.52%
5Y Avg
-384.82%
Market Cap
$112.69M
Return on Assets (ROA)
-31.75%
TTM Avg
-34.00%
3Y Avg
-32.33%
5Y Avg
-29.29%
Market Cap
$114.02M
Return on Assets (ROA)
-134.18%
TTM Avg
-145.83%
3Y Avg
-164.39%
5Y Avg
-180.40%
Market Cap
$114.06M
Return on Assets (ROA)
-72.42%
TTM Avg
-66.03%
3Y Avg
-45.57%
5Y Avg
-48.77%
Market Cap
$114.57M
Return on Assets (ROA)
-128.96%
TTM Avg
-127.49%
3Y Avg
-112.64%
5Y Avg
-129.28%
Market Cap
$115.76M
Return on Assets (ROA)
-0.05%
TTM Avg
-38.03%
3Y Avg
-60.31%
5Y Avg
-59.32%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MaxCyte, Inc. (MXCT) | $113.01M | -19.30% | -19.59% | -15.38% | -15.18% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $111.94M | -85.80% | -37.85% | -56.27% | -56.27% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $112.69M | -167.64% | -183.95% | -119.46% | -95.34% |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $112.51M | -48.90% | -85.01% | -256.52% | -384.82% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $112.69M | -31.75% | -34.00% | -32.33% | -29.29% |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.02M | -134.18% | -145.83% | -164.39% | -180.40% |
| Caribou Biosciences, Inc. (CRBU)vs › | $114.06M | -72.42% | -66.03% | -45.57% | -48.77% |
| Genelux Corporation (GNLX)vs › | $114.57M | -128.96% | -127.49% | -112.64% | -129.28% |
| Coya Therapeutics, Inc. (COYA)vs › | $115.76M | -0.05% | -38.03% | -60.31% | -59.32% |
| Apyx Medical Corporation (APYX)vs › | $109.74M | -14.14% | -26.48% | -30.34% | -26.58% |
ROA
-19.3%
ROE
-22.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -22.04% |
| 2024-12-31 | -17.14% |
| 2023-12-31 | -14.14% |
| 2022-12-31 | -8.22% |
| 2021-12-31 | -6.72% |
| 2020-12-31 | -22.82% |
| 2019-12-31 | -43.00% |
| 2018-12-31 | -36.55% |
| 2017-12-31 | -31.59% |
| 2016-12-31 | -20.82% |
| 2015-12-31 | -22.58% |
| 2014-12-31 | -29.15% |
| 2013-12-31 | -38.26% |
| 2012-12-31 | -69.97% |
